|
Bioo Scientific, founded in 2003, is a rapidly expanding biotech company located in Austin, Texas. In 2006, the company was converted from LLC to C-corporation. Bioo Scientific has applied for patents to protect its RNAi agent delivery technology, drug technologies and test kit products. Additionally, Bioo Scientific has been awarded numerous SBIR grants that support our innovative product development activities from the National Institutes of Health (NIH), the United States Department of Agriculture (USDA) and the National Science Foundation (NSF). In addition, we have developed contracts with global research companies and governmental agencies, which enable Bioo Scientific to fund new technology development and create jobs.
Bioo Scientific’s focus areas include:
Food and Feed Safety Products
Bioo Scientific is a market leader in the food and feed safety testing industry. We develop, manufacture and market a wide range of
food and feed safety products for the detection of microbial and industrial contaminants, natural toxins, and veterinary drug residues.
Life Science Products
Bioo Scientific offers a wide range of products to facilitate life science and preclinical research. In addition to our innovative RNAi
delivery solutions, our rapidly expanding product line includes gene-specific cytokine ELISAs, toxicology testing assays, tools for
working with small RNAs, and kits which simplify DNA and RNA isolation and PCR and protein detection
Services
Bioo Scientific has the experience and expertise to help you successfully complete preclinical drug development by designing,
performing, and documenting safety tests that meet regulatory requirements. A few of the services that our highly trained scientific
staff provides include in vivo RNAi/miRNA, immunohistochemistry, monoclonal antibody and protein and animal services at our USDA and OLAW approved animal facility.
Therapeutics
This fall Bioo Scientific is scheduled to launch a new division, BiooTherapeutics, which will focus on leveraging the therapeutic potential
of our proprietary technologies. Currently we have seven novel drug candidates in our pipeline.
|